Eosinophil Peroxidase : A Biomarker for Eosinophilic Chronic Rhinosinusitis Agnostic of Polyp Status
© 2023 The American Laryngological, Rhinological and Otological Society, Inc..
OBJECTIVE: To evaluate eosinophil peroxidase (EPX) as a biomarker for tissue levels of eosinophilia, cytokines, and chemokines within chronic rhinosinusitis (CRS).
METHODS: Twenty-eight subjects undergoing sinonasal surgery were prospectively enrolled. Ethmoid tissue was analyzed with an in-house EPX immunoassay and a 48-plex cytokine-chemokine array. Clinical severity was assessed using SNOT-22 and Lund-Mackay scores. Subjects were grouped as follows: controls, polyp status (CRS with [CRSwNP] and without nasal polyps [CRSsNP]), tissue eosinophilia (eosinophilic CRS [eCRS], non-eosinophilic CRS [neCRS]), or combinations thereof (eCRSwNP, eCRSsNP, neCRSsNP). eCRS was defined as >10 eosinophils per high power field (HPF). Subjects without CRS or asthma were enrolled as controls.
RESULTS: EPX was elevated in CRSwNP compared to control (p = 0.007), in eCRS compared to neCRS (p = 0.002), and in eCRSwNP along with eCRSsNP compared to neCRSsNP (p = 0.023, p = 0.015, respectively). eCRS displayed elevated IL-5 compared to neCRS (p = 0.005). No significant differences in EPX or IL-5 were observed between eCRSwNP and eCRSsNP. IL-5 was elevated in eCRSwNP (p = 0.019) compared neCRSsNP. Area under the receiver operator characteristic curve was 0.938 (95% CI, 0.835-1.00) for EPX and tissue eosinophilia, with an optimal cut-point of 470 ng/mL being 100% specific and 81.25% sensitive for tissue eosinophilia. Linear regression revealed a strong correlation between EPX and IL-5 (R2 = 0.64, p < 0.001). Comparing EPX and IL-5, only EPX displayed significant correlation with SNOT-22 (p = 0.04) and Lund-Mackay score (p = 0.004).
CONCLUSION: EPX is associated with tissue eosinophilia in CRS patients regardless of polyp status. EPX correlates with IL-5 and could be potentially considered a biomarker for anti-IL-5 therapies.
LEVEL OF EVIDENCE: 3 Laryngoscope, 134:69-78, 2024.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
The Laryngoscope - 134(2024), 1 vom: 20. Jan., Seite 69-78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Idler, Beau M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 18.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/lary.30787 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357571886 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357571886 | ||
| 003 | DE-627 | ||
| 005 | 20240218231839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/lary.30787 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM357571886 | ||
| 035 | |a (NLM)37255054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Idler, Beau M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eosinophil Peroxidase |b A Biomarker for Eosinophilic Chronic Rhinosinusitis Agnostic of Polyp Status |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 18.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The American Laryngological, Rhinological and Otological Society, Inc. | ||
| 520 | |a OBJECTIVE: To evaluate eosinophil peroxidase (EPX) as a biomarker for tissue levels of eosinophilia, cytokines, and chemokines within chronic rhinosinusitis (CRS) | ||
| 520 | |a METHODS: Twenty-eight subjects undergoing sinonasal surgery were prospectively enrolled. Ethmoid tissue was analyzed with an in-house EPX immunoassay and a 48-plex cytokine-chemokine array. Clinical severity was assessed using SNOT-22 and Lund-Mackay scores. Subjects were grouped as follows: controls, polyp status (CRS with [CRSwNP] and without nasal polyps [CRSsNP]), tissue eosinophilia (eosinophilic CRS [eCRS], non-eosinophilic CRS [neCRS]), or combinations thereof (eCRSwNP, eCRSsNP, neCRSsNP). eCRS was defined as >10 eosinophils per high power field (HPF). Subjects without CRS or asthma were enrolled as controls | ||
| 520 | |a RESULTS: EPX was elevated in CRSwNP compared to control (p = 0.007), in eCRS compared to neCRS (p = 0.002), and in eCRSwNP along with eCRSsNP compared to neCRSsNP (p = 0.023, p = 0.015, respectively). eCRS displayed elevated IL-5 compared to neCRS (p = 0.005). No significant differences in EPX or IL-5 were observed between eCRSwNP and eCRSsNP. IL-5 was elevated in eCRSwNP (p = 0.019) compared neCRSsNP. Area under the receiver operator characteristic curve was 0.938 (95% CI, 0.835-1.00) for EPX and tissue eosinophilia, with an optimal cut-point of 470 ng/mL being 100% specific and 81.25% sensitive for tissue eosinophilia. Linear regression revealed a strong correlation between EPX and IL-5 (R2 = 0.64, p < 0.001). Comparing EPX and IL-5, only EPX displayed significant correlation with SNOT-22 (p = 0.04) and Lund-Mackay score (p = 0.004) | ||
| 520 | |a CONCLUSION: EPX is associated with tissue eosinophilia in CRS patients regardless of polyp status. EPX correlates with IL-5 and could be potentially considered a biomarker for anti-IL-5 therapies | ||
| 520 | |a LEVEL OF EVIDENCE: 3 Laryngoscope, 134:69-78, 2024 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IL-5 | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a eosinophil peroxidase | |
| 650 | 4 | |a eosinophilia | |
| 650 | 4 | |a interleukin 5 | |
| 650 | 4 | |a nasal polyps | |
| 650 | 4 | |a sinusitis | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Eosinophil Peroxidase |2 NLM | |
| 650 | 7 | |a EC 1.11.1.- |2 NLM | |
| 650 | 7 | |a Interleukin-5 |2 NLM | |
| 650 | 7 | |a EPX protein, human |2 NLM | |
| 650 | 7 | |a EC 1.11.1.7 |2 NLM | |
| 700 | 1 | |a Iijima, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Ochkur, Sergei I |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobsen, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Rank, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Kita, Hirohito |e verfasserin |4 aut | |
| 700 | 1 | |a Lal, Devyani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Laryngoscope |d 1945 |g 134(2024), 1 vom: 20. Jan., Seite 69-78 |w (DE-627)NLM000205370 |x 1531-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2024 |g number:1 |g day:20 |g month:01 |g pages:69-78 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/lary.30787 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2024 |e 1 |b 20 |c 01 |h 69-78 | ||